×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GH – guardant health, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
10:58 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/29
04:05 pm
gh
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Medium
Report
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
1/29
01:41 pm
gh
Alger Small Cap Focus Fund Q4 2025 Portfolio Update [Seeking Alpha]
Low
Report
Alger Small Cap Focus Fund Q4 2025 Portfolio Update [Seeking Alpha]
1/26
10:02 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/26
09:36 am
gh
Guardant Health: Look For Explosive Revenue Growth Ahead [Seeking Alpha]
Low
Report
Guardant Health: Look For Explosive Revenue Growth Ahead [Seeking Alpha]
1/23
07:09 pm
gh
Omics Lab Services: Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Agilent Technologies, Q2 Solutions, Flomics Biotech, QIAGEN, Thermo Fisher Scientific and More [Yahoo! Finance]
Low
Report
Omics Lab Services: Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Agilent Technologies, Q2 Solutions, Flomics Biotech, QIAGEN, Thermo Fisher Scientific and More [Yahoo! Finance]
1/22
09:21 am
gh
Guardant nabs approval for Guardant360 companion diagnostic for Braftovi [Seeking Alpha]
Low
Report
Guardant nabs approval for Guardant360 companion diagnostic for Braftovi [Seeking Alpha]
1/22
08:17 am
gh
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/22
05:45 pm
gh
Form 4 Guardant Health, Inc. For: Jan 21 Filed by: MIGNONE ROBERTO
Low
Report
Form 4 Guardant Health, Inc. For: Jan 21 Filed by: MIGNONE ROBERTO
1/22
05:45 pm
gh
Form 4 Guardant Health, Inc. For: Jan 21 Filed by: Monroe Terilyn J.
Low
Report
Form 4 Guardant Health, Inc. For: Jan 21 Filed by: Monroe Terilyn J.
1/22
05:44 pm
gh
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Talasaz AmirAli
Low
Report
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Talasaz AmirAli
1/22
05:43 pm
gh
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Eltoukhy Helmy
Low
Report
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Eltoukhy Helmy
1/22
05:42 pm
gh
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Chudova Darya
Low
Report
Form 5 Guardant Health, Inc. For: Dec 31 Filed by: Chudova Darya
1/21
04:10 pm
gh
Form 144 Guardant Health, Inc. Filed by: Monroe Terilyn J.
Low
Report
Form 144 Guardant Health, Inc. Filed by: Monroe Terilyn J.
1/20
04:48 pm
gh
Form 4 Guardant Health, Inc. For: Jan 17 Filed by: Hidalgo Medina Manuel
Low
Report
Form 4 Guardant Health, Inc. For: Jan 17 Filed by: Hidalgo Medina Manuel
1/16
04:40 pm
gh
Form 4 Guardant Health, Inc. For: Jan 15 Filed by: Tariq Musa
Low
Report
Form 4 Guardant Health, Inc. For: Jan 15 Filed by: Tariq Musa
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Q2/2019 6/30/2019 EPS -0.130 ZacksConsensus -0.340 ActVsEst 0.210 - Beat
20.5%
5/9 Q1/2019 3/31/2019 EPS -0.300 ZacksConsensus -0.350 ActVsEst 0.050 - Beat 18.6%
2/27 Form 4 Guardant Health, Inc. For: Feb 25 Filed by: CLARK IAN T 12.9%
3/3 Form 4 Guardant Health, Inc. For: Feb 28 Filed by: Nishar Dipchand 12.4%
11/7 Q3/2019 9/30/2019 EPS -0.140 ZacksConsensus -0.390 ActVsEst 0.250 - Beat 12.2%
3/25 Form 4 Guardant Health, Inc. For: Mar 23 Filed by: BERTOCCI DEREK A 8.0%
2/25 Guardant Health Inc (GH) Q4 2019 Earnings Call Transcript [The Motley Fool] 7.5%
5/23 Form EFFECT Guardant Health, Inc. 6.5%
2/11 Form 4/A Guardant Health, Inc. For: Dec 20 Filed by: Talasaz AmirAli 6.3%
4/9 Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer 6.3%
5/9 Q1/2019 3/31/2019 EPS -0.300 ZacksConsensus -0.350 ActVsEst 0.050 - Beat 18.6%
2/27 Form 4 Guardant Health, Inc. For: Feb 25 Filed by: CLARK IAN T 12.9%
3/3 Form 4 Guardant Health, Inc. For: Feb 28 Filed by: Nishar Dipchand 12.4%
11/7 Q3/2019 9/30/2019 EPS -0.140 ZacksConsensus -0.390 ActVsEst 0.250 - Beat 12.2%
3/25 Form 4 Guardant Health, Inc. For: Mar 23 Filed by: BERTOCCI DEREK A 8.0%
2/25 Guardant Health Inc (GH) Q4 2019 Earnings Call Transcript [The Motley Fool] 7.5%
5/23 Form EFFECT Guardant Health, Inc. 6.5%
2/11 Form 4/A Guardant Health, Inc. For: Dec 20 Filed by: Talasaz AmirAli 6.3%
4/9 Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer 6.3%
TOP News Decliners
3/15
Coronavirus Bear Market: Where to Invest $5,000 Right Now [The Motley Fool]
-12.6%
3/6 Form 4 Guardant Health, Inc. For: Mar 04 Filed by: Kaul Samir -11.3%
2/24 Q4/2019 12/31/2019 EPS -0.270 ZacksConsensus -0.300 ActVsEst 0.030 - Beat -10.2%
2/28 Form 4 Guardant Health, Inc. For: Feb 26 Filed by: Kaul Samir -9.2%
5/8 The Wall Street Journal: SoftBank’s Vision Fund positioned for big haul in Uber IPO [MarketWatch] -7.5%
8/8 Guardant Health Inc (NASDAQ: GH) was given a new $110.00 price target on by analysts at Cowen Inc. They now have a "buy" rating on the stock. -6.9%
5/10 Form 4 Guardant Health, Inc. For: May 10 Filed by: BERTOCCI DEREK A -6.0%
3/11 Guardant Health Inc (NASDAQ: GH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.0%
10/5 3 Top Healthcare Stocks to Buy in October [The Motley Fool] -6.0%
9/13 Form 4 Guardant Health, Inc. For: Sep 11 Filed by: SVF Endurance (Cayman) Ltd -5.7%
3/6 Form 4 Guardant Health, Inc. For: Mar 04 Filed by: Kaul Samir -11.3%
2/24 Q4/2019 12/31/2019 EPS -0.270 ZacksConsensus -0.300 ActVsEst 0.030 - Beat -10.2%
2/28 Form 4 Guardant Health, Inc. For: Feb 26 Filed by: Kaul Samir -9.2%
5/8 The Wall Street Journal: SoftBank’s Vision Fund positioned for big haul in Uber IPO [MarketWatch] -7.5%
8/8 Guardant Health Inc (NASDAQ: GH) was given a new $110.00 price target on by analysts at Cowen Inc. They now have a "buy" rating on the stock. -6.9%
5/10 Form 4 Guardant Health, Inc. For: May 10 Filed by: BERTOCCI DEREK A -6.0%
3/11 Guardant Health Inc (NASDAQ: GH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.0%
10/5 3 Top Healthcare Stocks to Buy in October [The Motley Fool] -6.0%
9/13 Form 4 Guardant Health, Inc. For: Sep 11 Filed by: SVF Endurance (Cayman) Ltd -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: